TABLE 8. Antimalarial drug resistance marker results among Plasmodium falciparum specimens, by drug and region of malaria acquisition — United States, 2018.
| Resistance markers | Region |
|||
|---|---|---|---|---|
| Africa No. (%) | Asia No. (%) | Unknown* No. (%) | Total No. (%) | |
|
Pyrimethamine
|
98 (97.0)
|
1 (1.0)
|
2 (2.0)
|
101 (100)
|
| No resistance markers |
2 (2.0) |
0 (0) |
0 (0) |
2 (2.0)
|
| 1 resistance marker |
0 (0) |
0 (0) |
0 (0) |
0 (0)
|
| 2 resistance markers |
5 (5.0) |
1 (1.0) |
0 (0) |
6 (5.9)
|
| 3 or more resistance markers |
91 (90.1) |
0 (0) |
2 (2.0) |
93 (92.1)
|
|
Sulfadoxine
|
100 (97.1)
|
1 (1.0)
|
2 (1.9)
|
103 (100)
|
| No resistance markers |
52 (50.5) |
1 (1.0) |
1 (1.0) |
54 (52.4)
|
| 1 resistance marker |
26 (25.2) |
0 (0) |
1 (1.0) |
27 (26.2)
|
| 2 resistance markers |
15 (14.6) |
0 (0) |
0 (0) |
15 (14.6)
|
| 3 or more resistance markers |
7 (6.8) |
0 (0) |
0 (0) |
7 (6.8)
|
|
Chloroquine
|
107 (97.3)
|
1 (0.9)
|
2 (1.8)
|
110 (100)
|
| No resistance markers |
58 (52.7) |
0 (0) |
2 (1.8) |
60 (54.5)
|
| 1 resistance marker |
0 (0) |
0 (0) |
0 (0) |
0 (0)
|
| 2 resistance markers |
0 (0) |
1 (0.9) |
0 (0) |
1 (0.9)
|
| 3 resistance markers |
49 (44.6) |
0 (0) |
0 (0) |
49 (44.5)
|
|
Mefloquine
|
97 (98.0)
|
1 (1.0)
|
1 (1.0)
|
99 (100)
|
| No resistance markers |
95 (96.0) |
1 (1.0) |
1 (1.0) |
97 (98.0)
|
| 1 resistance marker |
2 (2.0) |
0 (0) |
0 (0) |
2 (2.0)
|
|
Atovaquone
|
94 (97.9)
|
1 (1.0)
|
1 (1.0)
|
96 (100)
|
| No resistance markers |
94 (97.9) |
1 (1.0) |
1 (1.0) |
96 (100)
|
|
Artemisinin
|
107 (97.3)
|
1 (0.9)
|
2 (1.8)
|
110 (100)
|
| No resistance markers | 107 (97.3) | 1 (0.9) | 2 (1.8) | 110 (100) |
* There were no specimens for molecular resistance marker analysis acquired from South America, Central America and the Caribbean, or Oceania.